Publications Office of the EU
Open House Pharmaceutical discount contracts Announcement of concluded contracts 13.08.2025 - 12.09.2025 - EU tenders
DisplayCustomHeader
MyPortal
Language Selector
English
BasketSummary
Procurement Detail Actions Portlet

Utilities

Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates text translated automatically in your browsing language

Open House Pharmaceutical discount contracts Announcement of concluded contracts 13.08.2025 - 12.09.2025

Overview
  • Today
    12/05/2026
Status
Submission closed
Type of contract
Supplies
Subject for Renewal
No
Buyer
AOK Bayern - Die Gesundheitskasse
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: DE212 München, Kreisfreie Stadt
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
Not available
Procedure details
Tender reference number
25-127
Description

With this notice, AOK Bayern publishes, for reasons of transparency, all contracts concluded within the framework of the Open House procedures for drug discount agreements pursuant to Section 130a(8) of the German Social Code (SGB) V and Section 130a(8)(c) of the German Social Code (SGB) V in the period from 13 August 2025 to 12 September 2025. AOK Bayern intends to conclude non-exclusive discount agreements with all interested pharmaceutical companies on the active substances mentioned in the respective procedure in accordance with § 130a(8) SGB V or § 130a(8) SGB V. AOK Bayern offers all interested pharmaceutical companies that meet the eligibility requirements listed below the conclusion of identical and non-individually negotiable discount agreements. Conclusion of a contract is possible at any time during the term. Contracts may be terminated with a notice period of one month to the end of the month. Upon the entry into force of a rebate agreement for medicinal products with the active substance subject to the contract concluded by a federal or state-specific, open procedure, the open-house agreements automatically expire for the corresponding term. A contract is concluded with all interested pharmaceutical companies who prove their suitability by means of a completed and signed self-declaration of reliability. Details can be found in the contract notice for the respective Open House procedure in the Official Journal of the European Union. Contracts concluded between 13.08.2025 and 12.09.2025: Adalimumab: 2care4 ApS, 1 0 1 Carefarm GmbH, Aaragon Pharma s.r.o., Abacus Medicine AS, Amgen GmbH, axicorp Pharma BV, axicorp Pharma GmbH, Biocon Biologics Germany GmbH, Biogen GmbH, Celltrion Healthcare Deutschland GmbH, Fresenius Kabi Deutschland GmbH, Hexal AG, kohlpharma GmbH, Orifarm GmbH, Originalis BV, Paranova Pack A/S, Pfizer Pharma GmbH, PB Pharma GmbH Amifampridin: Hormosan Pharma GmbH Aripiprazole: Otsuka Pharma GmbH Budesonide: CC Pharma GmbH, Medical Valley Invest AB Dimethyl fumarate: Abdi Farma GmbH, Accord Healthcare S.L.U., Glenmark Arzneimittel GmbH, Hexal AG, ratiopharm GmbH, STADAPHARM GmbH, Viatris Healthcare GmbH, Zentiva Pharma GmbH Erythropoietin alfa: Abacus Medicine AS, Hexal AG, kohlpharma GmbH, MEDICE Arzneimittel Pütter GmbH & Co. KG, Orifarm GmbH Erythropoietin zeta: Abacus Medicine AS Etanercept: axicorp Pharma GmbH Omalizumab: Paranova Pack A/S, Celltrion Healthcare Deutschland GmbH, EurimPharm Arzneimittel GmbH Pazopanib: kohlpharma GmbH Peginterferon beta-1a: Originalis BV Pyridostigmine: Aliud Pharma GmbH, Hormosan Pharma GmbH, Stadapharm GmbH, Viatris Healthcare GmbH Raltegravir: kohlpharma GmbH Rivaroxaban FTA (except 2,5): 1 A Pharma GmbH, Abdi Farma GmbH, AbZ-Pharma GmbH, Aliud Pharma GmbH, Aristo Pharma GmbH, Basics GmbH, Stadapharm GmbH, EMRA-med Arzneimittel GmbH, Glenmark Arzneimittel GmbH, ratiopharm GmbH, Stadapharm GmbH, Viatris Healthcare GmbH, Zentiva Pharma GmbH, Denk Pharma GmbH & Co. KG Ustekinumab: kohlpharma GmbH, FD Pharma GmbH Anakinra: CC Pharma GmbH Tacrolimus: Ascend GmbH Brinzolamide and Brimonidine: Cranach Pharma GmbH Dornase alfa: Roche Pharma AG Eltrombopag: Betapharm Arzneimittel GmbH Emtricitabine, tenofovir disoproxil and rilpirivin: Medicopharm AG Epinephrine: ALK-Abello Arzneimittel GmbH Formoterol, glycopyrronium bromide and budesonide: AstraZeneca GmbH Leuprorelin: CC Pharma GmbH, EurimPharm Arzneimittel GmbH

Submission Method
Not available
Tenders may be submitted
Not available
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
The procurement involves the establishment of a framework agreement
Conditions for opening tenders (date)
Not available
Place of performance
DE Deutschland
Any country
CPV code

33600000 - Pharmaceutical products

Award method
Criterion:
Type: price
Description: Preis
Weight (percentage, exact):
Estimated value
Not available
Final contracted value
Not available
Award of contract
Not available
Documents
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.